Gain Therapeutics Inc
gaintherapeutics.comWhat Do They Do?
Develops small-molecule drug candidates for neurological, lysosomal storage and metabolic diseases, using a computational platform to identify protein sites and compounds.
10-K for FY2025, filed Mar 26, 2026We are a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including…View ↗
Our Magellan™ PlatformView ↗
A majority of disease-causing proteins (up to 90%) cannot be targeted due to the lack of a known binding site. Our Magellan™ platform was…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 11, 2026
−$4.7MView ↗
- ▼ −20% (Loss)
- vs −$5.8M in Q2 FY2025
Broader Parkinson’s target group
The earlier report framed the lead candidate around mutation-linked Parkinson’s; the latest says it is being evaluated in Parkinson’s with or without the mutation.
10-K for FY2022, filed Mar 23, 2023 10-K for FY2025, filed Mar 26, 2026Our Lead Product Candidate: GT-02287 for the Treatment of GBA1 Parkinson’s diseaseView ↗
GT-02287 - our lead product candidate, for the treatment of Parkinson’s disease, is currently being evaluated in a Phase 1b study in people…View ↗
Who Do They Compete With?
Competes with Vanqua Bio, BIAL, Caraway Therapeutics, Prevail Therapeutics, and Voyager Therapeutics
10-K for FY2025, filed Mar 26, 2026The biotechnology and pharmaceutical industries are characterized by the rapid evolution of technologies and understanding of disease…View ↗
Loading...
